Collectively, these in vitro findings suggest that liraglutide alleviates ox-LDL-induced endothelial dysfunction through GLP-1R-dependent down-regulation of the LOX-1/NOX4/NF-κB signaling pathway. The gene discussed is OLR1; the disease is endothelial dysfunction.